Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER_GOV × Myelodysplastic Syndromes × Azacitidine × Clear all

Phase

Status

Sponsor Class

OTHER 78 INDUSTRY 58 NIH 9 NETWORK 2 OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1 Myeloid 1

Conditions

Leukemia, Myeloid, Acute 4 Myelodysplastic Syndromes 1 Leukemia, Myelomonocytic, Chronic 1

Interventions

Cyclophosphamide 2 treosulfan 1 defactinib 1 decitabine and cedazuridine drug combination 1 cedazuridine 1 cc-486 1 Human Papillomavirus Recombinant Vaccine nonavalent 1 Decitabine 1 Busulfan 1 Azacitidine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03493646 2024-05-28

Evaluating in Vivo AZA Incorporation in Mononuclear Cells Following Vidaza or CC486

Kirby Institute

Phase 2 Completed

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡